A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small...

Por Garon, Edward B, Neidhart, Jeffrey D, Gabrail, Nashat Y, de Oliveira, Moacyr R, Balkissoon, Jai, Kabbinavar, Fairooz
Publicado no Onco Targets Ther (2016)

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Por Salama, Carlos, Han, Jian, Yau, Linda, Reiss, William G., Kramer, Benjamin, Neidhart, Jeffrey D., Criner, Gerard J., Kaplan-Lewis, Emma, Baden, Rachel, Pandit, Lavannya, Cameron, Miriam L., Garcia-Diaz, Julia, Chávez, Victoria, Mekebeb-Reuter, Martha, Lima de Menezes, Ferdinando, Shah, Reena, González-Lara, Maria F., Assman, Beverly, Freedman, Jamie, Mohan, Shalini V.
Publicado no N Engl J Med (2020)

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Por Weiss, Glen J., Chao, Joseph, Neidhart, Jeffrey D., Ramanathan, Ramesh K., Bassett, Dawn, Neidhart, James A., Choi, Chung Hang J., Chow, Warren, Chung, Vincent, Forman, Stephen J., Garmey, Edward, Hwang, Jungyeon, Kalinoski, D. Lynn, Koczywas, Marianna, Longmate, Jeffrey, Melton, Roger J., Morgan, Robert, Oliver, Jamie, Peterkin, Joanna J., Ryan, John L., Schluep, Thomas, Synold, Timothy W., Twardowski, Przemyslaw, Davis, Mark E., Yen, Yun
Publicado em 2013